Corcept Therapeutics Newsroom

Corcept Therapeutics Presents Phase 3 Long-Term Extension Study Of Relacorilant Demonstrated Durable Cardiometabolic Improvements In Patients With Hypercortisolism

BenzingaDec 16 08:04 ET

Express News | Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients With Hypercortisolism

ReutersDec 16 08:00 ET

Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating

Moomoo NewsDec 13 07:33 ET · Ratings

Corcept Therapeutics (CORT) Receives a Buy From Truist Financial

TipRanksDec 13 07:16 ET · Ratings

Insider Sale: Director at $CORT (CORT) Sells 2,200 Shares

Quiver QuantitativeDec 12 17:01 ET

Corcept Announces Primary Endpoint Met In Treatment Phase Of CATALYST Trial In Patients With Hypercortisolism And Difficult-To-Control Diabetes

BenzingaDec 12 16:09 ET

Express News | Corcept Therapeutics Inc - Korlym Safety Profile Consistent With Label, No New Side Effects

ReutersDec 12 16:05 ET

Express News | Corcept Announces Positive Results in Treatment Phase of Catalyst Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

ReutersDec 12 16:05 ET

CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study

Zacks Dec 12 09:35 ET

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

MT NewswiresDec 12 09:07 ET

Optimistic Outlook for Corcept Therapeutics Amid Promising Developments and Regulatory Advantages

TipRanksDec 12 06:55 ET

Correction to Corcept Therapeutics Shares Fall Article

Dow JonesDec 11 17:02 ET

Corcept Therapeutics Fall 7% After ALS Drug Fails Trial

WSJDec 11 16:49 ET

Express News | Corcept Therapeutics Inc - Dazucorilant Patients Experienced More Gastrointestinal Upset Than Placebo

ReutersDec 11 16:10 ET

Corcept Announces Results From Phase 2 Study Of Dazucorilant In Patients With Amyotrophic Lateral Sclerosis; DAZALS Did Not Meet Its Primary Endpoint, Which Was The Change From Baseline In The ALS Functional Rating Scale-Revised In Patients Who...

BenzingaDec 11 16:08 ET

Express News | Corcept Therapeutics Inc - Long-Term Extension Study to Assess Overall Survival in March 2025

ReutersDec 11 16:07 ET

Express News | Corcept Therapeutics Inc - No Deaths in 300 Mg Arm, 5 Deaths in Placebo Group

ReutersDec 11 16:06 ET

Express News | Corcept Therapeutics Inc - Dazals Study Did Not Meet Primary Endpoint

ReutersDec 11 16:06 ET

Express News | Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

ReutersDec 11 16:05 ET

S&P 500 Futures Rise In Premarket Trading; Bausch + Lomb, Bio-Techne Lag

Dow JonesDec 11 07:30 ET